Machtay 2007.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 148, head and neck cancer (stage I‐IV); concomitant treatment: radiotherapy
Interventions	drug = Epoetin alpha dose = 40000 IU sc weekly hb‐target = 12.5‐14 g/dL (women), 13.5‐16 g/dL (men) planned ESA duration = 8 weeks
Outcomes	Primary: local regional control tumor response; secondary: overall survival, patterns of failure, local‐regional progression‐free survival, Hb, toxicity, QoL
Notes	study number = 87660
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization